

# Myeloma Pathways: Multiple Myeloma

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

**Pathology:** \_\_\_\_\_

**Stage:** \_\_\_\_\_

**Line of Therapy:**  1<sup>st</sup> Line  2<sup>nd</sup> Line  3<sup>rd</sup> Line  3<sup>rd</sup> Line+  
 Maintenance

**ECOG Performance Status:** \_\_\_\_\_ **ICD-10 Code:** \_\_\_\_\_

**Biomarkers/Characteristics:** (select all that apply)

Transplant Candidate:  No  Yes

## Primary/First Line of Therapy (1<sup>st</sup> Line) | Transplant Candidates

**VRD/VDR:** bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone

**D-VTd:** daratumumab (Darzalex), bortezomib (Velcade), thalidomide, and dexamethasone

## Primary/First Line of Therapy (1<sup>st</sup> Line) | Non-Transplant Candidates

**CyBorD or VDC:** bortezomib (Velcade), cyclophosphamide, and dexamethasone

**DRd:** daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone

**R-dex:** lenalidomide (Revlimid) and low-dose dexamethasone

**VRD/VDR:** bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone

**VD:** bortezomib (Velcade) and dexamethasone

## Maintenance Therapy | Post-Transplant

Lenalidomide (Revlimid)

## Relapsed Disease | Second and Subsequent Lines of Therapy (2<sup>nd</sup> Line+)

**CRd or KRd:** carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone

**DRD:** daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone

**DVD:** daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone

**PVd:** pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone\*

\* Eligible only if patient has received prior therapy with lenalidomide and proteasome inhibitor

**Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.**



8600 West Bryn Mawr Avenue  
South Tower - Suite 800 Chicago, IL 60631  
[www.aimspecialtyhealth.com](http://www.aimspecialtyhealth.com)

Last review: 2/15/2022 | Effective date: 4/25/2022

Appropriate.Safe.Affordable  
© 2022 AIM Specialty Health  
9016-0422